Edgar Filing: ATRIX LABORATORIES INC - Form 4

ATRIX LABORATORIES INC

Form 4

Common

Stock

11/19/2004

November 23, 2004

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISS								OMB APPROVAL			
	OIVIII	ED STATE			ND EXCH D.C. 2054		COMMISSION	OMB Number:	3235-0287		
Check th if no long	ner	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							January 31, 2005		
subject to Section 1 Form 4 o	51 A1 16. or								verage rs per 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
Print or Type I	Responses)										
1. Name and ABETHUNE	Address of Repor	2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer						
			ATRIX LABORATORIES INC [ATRX]				(Check all applicable)				
(Last) (First) (Middle) 2579 MIDPOINT DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 11/19/2004				X Director X Officer (give below)		Owner er (specify		
				ndment, Da nth/Day/Year	nte Original		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
FORT COL	LINS, CO 80	525						More than One Re			
(City)	(State)	(Zip)	Tabl	e I - Non-D	Derivative Se	curities Acq	uired, Disposed of	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Y	saction Date 2A. Deemed /Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Code V

D

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Amount

146,477 D

(D) Price

<u>(1)</u>

0

Edgar Filing: ATRIX LABORATORIES INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 9.75	11/19/2004		D		60,000	(2)	06/02/2010	Common Stock	60,000
Stock Option	\$ 9.5	11/19/2004		D		50,000	(3)	08/03/2010	Common Stock	50,000
Stock Option	\$ 12.875	11/19/2004		D		50,000	<u>(4)</u>	08/18/2010	Common Stock	50,000
Stock Option	\$ 15.125	11/19/2004		D		20,000	<u>(5)</u>	09/05/2010	Common Stock	20,000
Stock Option	\$ 17.6875	11/19/2004		D		100,000	<u>(6)</u>	01/02/2011	Common Stock	100,000
Stock Option	\$ 5	11/19/2004		D		100,503	<u>(7)</u>	08/06/2011	Common Stock	100,503
Stock Option	\$ 22.62	11/19/2004		D		25,000	<u>(8)</u>	05/22/2012	Common Stock	25,000
Stock Option	\$ 25	11/19/2004		D		25,000	<u>(9)</u>	05/22/2012	Common Stock	25,000
Stock Option	\$ 28	11/19/2004		D		25,000	(10)	05/22/2012	Common Stock	25,000
Stock Option	\$ 30	11/19/2004		D		25,000	<u>(11)</u>	05/22/2012	Common Stock	25,000
Stock Option	\$ 16.46	11/19/2004		D		150,000	<u>(12)</u>	04/28/2013	Common Stock	150,000
Stock Option	\$ 31	11/19/2004		D		50,000	<u>(13)</u>	05/06/2014	Common Stock	50,000

Reporting Owners

Reporting Owner Name / Address	Keiauonsinps						
	Director	10% Owner	Officer	Other			
BETHUNE DAVID R							
2579 MIDPOINT DRIVE	X		Chief Executive Officer				
FORT COLLINS, CO 80525							

Reporting Owners 2

Edgar Filing: ATRIX LABORATORIES INC - Form 4

Signatures

Sarah Watson, Attorney-in-Fact for David R.
Bethune

11/23/2004

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposed of pursuant to merger agreement between issuer and QLT Inc. for 146,477 shares of QLT common stock having a market value of \$15.42 per share as reported on NASDAQ on the effective date of the merger, and \$2,140,028.90 in cash.
- This option, which provided for vesting in three equal annual installments beginning on June 2, 2001, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 114,244 shares of QLT Inc. common stock for \$5.13 per share.
- (3) This option, which provided for vesting in three equal annual installments beginning on August 3, 2001, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 95,203 shares of QLT Inc. common stock for \$4.99 per share.
- (4) This option, which provided for vesting in three equal annual installments beginning on August 18, 2001, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 95,203 shares of QLT Inc. common stock for \$6.77 per share.
- (5) This option, which provided for vesting in three equal annual installments beginning on September 5, 2001, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 38,081 shares of QLT Inc. common stock for \$7.95 per share.
- This option, which provided for vesting in three equal annual installments beginning on January 2, 2002, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 190,405 shares of QLT Inc. common stock for \$9.29 per share.
- (7) This option, which vested immediately on August 6, 2001, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 191,364 shares of QLT Inc. common stock for \$2.63 per share.
- (8) This option, which provided for vesting in two equal annual installments beginning on May 22, 2003, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 47,600 shares of QLT Inc. common stock for \$11.88 per share.
- (9) This option, which provided for vesting in two equal annual installments beginning on May 22, 2003, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 47,601 shares of QLT Inc. common stock for \$13.13 per share.
- (10) This option, which provided for vesting in two equal annual installments beginning on May 22, 2003, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 47,601 shares of QLT Inc. common stock for \$14.71 per share.
- (11) This option, which provided for vesting in two equal annual installments beginning on May 22, 2003, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 47,601 shares of QLT Inc. common stock for \$15.76 per share.
- (12) This option, which provided for vesting in three equal annual installments beginning on April 28, 2004, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 285,610 shares of QLT Inc. common stock for \$8.65 per share.
- (13) This option, which provided for vesting in three equal annual installments beginning on May 6, 2004, was assumed by QLT Inc. in the merger and replaced with a fully vested option to purchase 95,203 shares of QLT Inc. common stock for \$16.29 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3